Skip to main content
Caplight Logo









VacV Biotherapeutics

VacV Biotherapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://vacvbtx.com/

Last Round

Grant

Aug 28, 2024

Total Funding Raised

$3.62M

Company Overview

VacV Biotherapeutics is a biotechnology company developing a novel cancer immunotherapy platform based on its proprietary oncolytic virus technology to treat solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

oncolytic virus therapyoncolytic Vaccinia viruscancer-killing viruscancer immunotherapyimmuno-oncologyvirotherapysolid tumor therapyengineered virus therapysystemic deliverypre-clinical biotechglioblastomaintravenous deliverypancreatic cancerDIPGacademic spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VacV Biotherapeutics Comparables

Compare VacV Biotherapeutics with similar companies based on industry and business-model similarity.

VacV Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Omios Biologics
86%
ReIGNITE Therapeutics
83%
KaliVir Immunotherapeutics
81%

VacV Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 28, 2024
SeedOct 26, 2022

Key People

Founding team and executive leadership

Yidan Zhang

Global CEO

Executive Team

VacV Biotherapeutics Investors

Notable investors and investment history

VacV Biotherapeutics investors
InvestorRounds
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 91% MoM.

  • Jul 6, 2025

    Monthly visitors increased 371% MoM, from 51 to 240.

VacV Biotherapeutics Filings

Explore SEC and related filing metadata, where available.

VacV Biotherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about VacV Biotherapeutics's valuation, stock price, and market status.

Is VacV Biotherapeutics a public or private company?

VacV Biotherapeutics is a private company.

What is the current stock price of VacV Biotherapeutics?

VacV Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is VacV Biotherapeutics worth (valuation)?

Valuation information for VacV Biotherapeutics is not publicly available.

Can I buy VacV Biotherapeutics stock?

VacV Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was VacV Biotherapeutics's last funding round?

VacV Biotherapeutics's most recent funding round was Grant on August 28, 2024.

Who are the main investors in VacV Biotherapeutics?

Key investors in VacV Biotherapeutics include Innovate UK.

Will VacV Biotherapeutics IPO soon?

No public IPO plans have been announced for VacV Biotherapeutics.

How can I track VacV Biotherapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VacV Biotherapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHelsinki
Employee Range5
Year Founded2021
Last FundingAug 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?